FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174226404> ?p ?o ?g. }

• W3174226404 endingPage "2170" @default.
• W3174226404 startingPage "2159" @default.
• W3174226404 abstract "Abstract Background & Aims While direct oral anticoagulants (DOACs) are increasingly used in patients with liver disease, safety data especially in advanced chronic liver disease (ACLD) are limited. Methods Liver disease patients receiving DOAC treatment (ACLD: n = 104; vascular liver disease: n = 29) or vitamin K antagonists (VKA)/low‐molecular‐weight heparin (LMWH; ACLD: n = 45; vascular: n = 13) between January 2010 and September 2020 were retrospectively included. Invasive procedures and bleeding events were recorded. Calibrated anti‐Xa peak levels and thrombomodulin‐modified thrombin generation assays (TM‐TGAs) were measured in a subgroup of 35/28 DOAC patients. Results Among patients receiving DOAC, 55 (41.3%) had advanced liver dysfunction (Child‐Pugh‐stage [CPS] B/C) and 66 (49.6%) had experienced decompensation. Overall, 205 procedures were performed in 60 patients and procedure‐related bleedings occurred in 7 (11.7%) patients. Additionally, 38 (28.6%) patients experienced spontaneous (15 minor, 23 major) bleedings during a median follow‐up of 10.5 (IQR: 4.0‐27.8) months. Spontaneous bleedings in ACLD patients were more common in CPS‐B/C (at 12 months: 36.9% vs CPS‐A: 15.9%, subdistribution hazard ratio [SHR]: 3.23 [95% CI: 1.59‐6.58], P < .001), as were major bleedings (at 12 months: 22.0% vs 5.0%, SHR: 5.82 [95% CI: 2.00‐16.90], P < .001). Importantly, CPS (adjusted SHR: 4.12 [91% CI: 1.82‐9.37], P < .001), but not the presence of hepatocellular carcinoma or varices, was independently associated with major bleeding during DOAC treatment. Additionally, ACLD patients experiencing bleeding had worse overall survival (at 12 months: 88.9% vs 95.0% without bleeding; P < .001). Edoxaban anti‐Xa peak levels were higher in patients with CPS‐B/C (345 [95% CI: 169‐395] vs CPS‐A: 137 [95% CI: 96‐248] ng/mL, P = .048) and were associated with lower TM‐TGA. Importantly, spontaneous bleeding rates were comparable to VKA/LMWH patients. Conclusions Anticoagulants including DOACs should be used with caution in patients with advanced liver disease due to a significant rate of spontaneous bleeding events." @default.
• W3174226404 created "2021-07-05" @default.
• W3174226404 creator A5001144757 @default.
• W3174226404 creator A5006745092 @default.
• W3174226404 creator A5015899523 @default.
• W3174226404 creator A5024485263 @default.
• W3174226404 creator A5029138179 @default.
• W3174226404 creator A5033190484 @default.
• W3174226404 creator A5046244856 @default.
• W3174226404 creator A5048534007 @default.
• W3174226404 creator A5055058026 @default.
• W3174226404 creator A5067605507 @default.
• W3174226404 creator A5069560637 @default.
• W3174226404 creator A5074302578 @default.
• W3174226404 creator A5074325776 @default.
• W3174226404 creator A5087316703 @default.
• W3174226404 creator A5090751499 @default.
• W3174226404 date "2021-07-10" @default.
• W3174226404 modified "2023-10-16" @default.
• W3174226404 title "Safety of direct oral anticoagulants in patients with advanced liver disease" @default.
• W3174226404 cites W1480212256 @default.
• W3174226404 cites W1968641413 @default.
• W3174226404 cites W1997637512 @default.
• W3174226404 cites W2010968851 @default.
• W3174226404 cites W2038981426 @default.
• W3174226404 cites W2090387429 @default.
• W3174226404 cites W2094642669 @default.
• W3174226404 cites W2096246254 @default.
• W3174226404 cites W2096808849 @default.
• W3174226404 cites W2115787552 @default.
• W3174226404 cites W2119768870 @default.
• W3174226404 cites W2120964526 @default.
• W3174226404 cites W2139785591 @default.
• W3174226404 cites W2145791480 @default.
• W3174226404 cites W2166467296 @default.
• W3174226404 cites W2211816300 @default.
• W3174226404 cites W2324879890 @default.
• W3174226404 cites W2468468427 @default.
• W3174226404 cites W2533474819 @default.
• W3174226404 cites W2534376183 @default.
• W3174226404 cites W2543286672 @default.
• W3174226404 cites W2596888165 @default.
• W3174226404 cites W2761154221 @default.
• W3174226404 cites W2786491861 @default.
• W3174226404 cites W2792134434 @default.
• W3174226404 cites W2809833128 @default.
• W3174226404 cites W2885107848 @default.
• W3174226404 cites W2886985238 @default.
• W3174226404 cites W2909761474 @default.
• W3174226404 cites W2909825377 @default.
• W3174226404 cites W2917499147 @default.
• W3174226404 cites W2918914542 @default.
• W3174226404 cites W2950337259 @default.
• W3174226404 cites W2970287425 @default.
• W3174226404 cites W2989714602 @default.
• W3174226404 cites W3030222297 @default.
• W3174226404 cites W3046707400 @default.
• W3174226404 cites W3048061620 @default.
• W3174226404 cites W3092901048 @default.
• W3174226404 cites W4242982898 @default.
• W3174226404 cites W571628560 @default.
• W3174226404 doi "https://doi.org/10.1111/liv.14992" @default.
• W3174226404 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8456813" @default.
• W3174226404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34152697" @default.
• W3174226404 hasPublicationYear "2021" @default.
• W3174226404 type Work @default.
• W3174226404 sameAs 3174226404 @default.
• W3174226404 citedByCount "28" @default.
• W3174226404 countsByYear W31742264042021 @default.
• W3174226404 countsByYear W31742264042022 @default.
• W3174226404 countsByYear W31742264042023 @default.
• W3174226404 crossrefType "journal-article" @default.
• W3174226404 hasAuthorship W3174226404A5001144757 @default.
• W3174226404 hasAuthorship W3174226404A5006745092 @default.
• W3174226404 hasAuthorship W3174226404A5015899523 @default.
• W3174226404 hasAuthorship W3174226404A5024485263 @default.
• W3174226404 hasAuthorship W3174226404A5029138179 @default.
• W3174226404 hasAuthorship W3174226404A5033190484 @default.
• W3174226404 hasAuthorship W3174226404A5046244856 @default.
• W3174226404 hasAuthorship W3174226404A5048534007 @default.
• W3174226404 hasAuthorship W3174226404A5055058026 @default.
• W3174226404 hasAuthorship W3174226404A5067605507 @default.
• W3174226404 hasAuthorship W3174226404A5069560637 @default.
• W3174226404 hasAuthorship W3174226404A5074302578 @default.
• W3174226404 hasAuthorship W3174226404A5074325776 @default.
• W3174226404 hasAuthorship W3174226404A5087316703 @default.
• W3174226404 hasAuthorship W3174226404A5090751499 @default.
• W3174226404 hasBestOaLocation W31742264041 @default.
• W3174226404 hasConcept C126322002 @default.
• W3174226404 hasConcept C207103383 @default.
• W3174226404 hasConcept C2776301958 @default.
• W3174226404 hasConcept C2776704044 @default.
• W3174226404 hasConcept C2777075537 @default.
• W3174226404 hasConcept C2777214474 @default.
• W3174226404 hasConcept C2778019345 @default.
• W3174226404 hasConcept C2778721985 @default.
• W3174226404 hasConcept C2779102576 @default.
• W3174226404 hasConcept C2779161974 @default.

• next